Nektar Therapeutics to Host Analyst & Investor Event at 2018 ASCO Annual Meeting

Monday, April 30, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

SAN FRANCISCO, April 30, 2018 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will host an analyst

and investor event with clinical investigators on Saturday, June 2, 2018 at 6:45 p.m. CDT in Chicago, IL during the 2018 American Society of Clinical Oncology
(ASCO) Meeting. The event will immediately follow the oral presentation of preliminary Phase 1/2 results of PIVOT, a study of NKTR-214 in combination with nivolumab, during the Developmental Therapeutics – Immunotherapy session at the ASCO meeting.

NKTR-214 is an investigational immune-stimulatory therapy designed to expand specific cancer-fighting CD8+ effector T cells and natural killer (NK) cells directly in the tumor micro-environment and increase expression of PD-1 on these immune cells.

Clinical investigators at the event will include Dr. Adi Diab, Assistant Professor, Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, Dr. Scott N. Gettinger, Associate Professor, Medical Oncology at the Yale Cancer Center and Dr. Nizar M. Tannir, Professor, Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center.

Investors and analysts are invited to listen to a live audio webcast of the event which will be accessible from the home page of the company's website The webcast will also be available for replay for two weeks following the event.

Details of the oral presentation for PIVOT results at ASCO are as follows:

Oral PresentationDate: Saturday, June 2, 2018, Presentation Time: 5:00 p.m. Central Daylight TimeSession Title: Developmental Therapeutics – ImmunotherapyPresentation Title: NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOTPresenter: Dr. Adi Diab, MD Anderson Cancer CenterLocation: McCormick Place, Hall B1

About Nektar TherapeuticsNektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at

Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements which can be identified by words such as: "will," "designed" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the expected benefits of NKTR-214.  Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) NKTR-214 is in early stage clinical development and the risk of failure remains high and failure can unexpectedly occur at any stage for one or more of the cancer indications being studied prior to regulatory approval due to lack of sufficient efficacy, safety considerations or other factors that impact drug development; (ii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of potential new drug candidates such as NKTR-214 is therefore very uncertain and unpredictable and could fail; (iii) patents may not issue from our patent applications for our drug candidates including NKTR-214, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (iv) certain other important risks and uncertainties set forth in Nektar's Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission on March 1, 2018. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Nektar Contacts:

For Investors: Jennifer Ruddock of Nektar Therapeutics415-482-5585

For Media:Jodi Sievers of Nektar Therapeutics415-482-5593

Dan Budwick of


Cision View original content:

SOURCE Nektar Therapeutics

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store